Jacobs Levy Equity Management
RVNC

Jacobs Levy Equity Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Jacobs Levy Equity Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-81,579
Closed -$210K – 1069
2024
Q2 		$210K Buy
+81,579
New +$279K ﹤0.01% 918
2023
Q1 		– Sell
-123,821
Closed -$2.29M – 1076
2022
Q4 		$2.29M Sell
123,821
-794,454
-87% -$18.2M 0.02% 528
2022
Q3 		$24.8M Buy
918,275
+854,755
+1,346% +$17.3M 0.2% 137
2022
Q2 		$878K Sell
63,520
-2,931
-4% -$45.1K 0.01% 776
2022
Q1 		$1.3M Sell
66,451
-169,073
-72% -$2.56M 0.01% 713
2021
Q4 		$3.84M Buy
+235,524
New +$3.93M 0.03% 486
2020
Q1 		– Sell
-65,176
Closed -$1.06M – 1111
2019
Q4 		$1.06M Sell
65,176
-182,115
-74% -$2.82M 0.01% 681
2019
Q3 		$3.21M Buy
247,291
+8,444
+4% +$103K 0.04% 412
2019
Q2 		$3.1M Buy
+238,847
New +$3.01M 0.04% 437
2016
Q3 		– Sell
-51,400
Closed -$699K – 1151
2016
Q2 		$699K Sell
51,400
-31,490
-38% -$557K 0.01% 676
2016
Q1 		$1.45M Buy
+82,890
New +$1.69M 0.03% 487

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

Jacobs Levy Equity Management's RVNC Position: Q3 2024 in Review

Jacobs Levy Equity Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 81,579 shares — an estimated $210K sold.

Jacobs Levy Equity Management first reported a position in RVNC in Q1 2016 and held it in 11 quarters. The position peaked at $24.8M in Q3 2022. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Jacobs Levy Equity Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 81,579 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $210K.
  • Jacobs Levy Equity Management first reported a position in Revance Therapeutics, Inc. in Q1 2016 and held it in 11 quarters.
  • Jacobs Levy Equity Management's Revance Therapeutics, Inc. position peaked at $24.8M in Q3 2022.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2024, filed 14 Nov 2024.